(Q38391533)

2 September 2017

1 reference

title

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation (English)

1 reference

2 September 2017

4

Jedd D Wolchok

1 reference

2 September 2017

Alexander M Lesokhin

1

1 reference

2 September 2017

Margaret K Callahan

series ordinal

2

1 reference

2 September 2017

Michael A Postow

series ordinal

3

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 March 2015

1 reference

Science Translational Medicine

2 September 2017

published in

1 reference

2 September 2017

volume

7

1 reference

2 September 2017

issue

280

1 reference

2 September 2017

page(s)

280sr1

1 reference

Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications.

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Lessons from Coley's Toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

The immune contexture in human tumours: impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Historical markers in the development of allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Positive and negative selection of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Immune surveillance against a solid tumor fails because of immunological ignorance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

T-cell exhaustion: characteristics, causes and conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CD28z CARs and armored CARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Molecular mechanisms of T cell co-stimulation and co-inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Ipilimumab: controversies in its development, utility and autoimmune adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

ICOS controls the pool size of effector-memory and regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe".

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

The TNF family in T cell differentiation and function--unanswered questions and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

OX40 is a potent immune-stimulating target in late-stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Combining radiotherapy and cancer immunotherapy: a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Epitope landscape in breast and colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Checkpoint blocking antibodies in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010274

Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2006.24.18_SUPPL.4609

Identifiers

DOI

10.1126/SCITRANSLMED.3010274

1 reference

2 September 2017

1 reference